SPRO Spero Therapeutics Inc

$SPRO my longtime local pharmacist and friend at a very busy walmart, who dispenses a lot of uti meds, tells me he expects Utebzi to likely be in stock sometime in november.

$SPRO "derived solely from the GSK payments due to Spero, until the loan balance is repaid. Following repayment, Spero will retain 35% of subsequent GSK payments related to sales of Utebzi, preserving potential long-term upside from the asset." for all the fools saying they sold the rights away.

$SPRO $ACXP $ARMP took a position in these 3 for plague stocks. Could get interesting if these go wild. ChatGPT saying these are best under $5 .

$SPRO the markets have somewhat reacted to Chinese drug licensing, but not anywhere close to where it is going to be. I'm betting this one will be one of the winners for when everyone starts paying real attention.

$SPRO so 200-300M n annual revenue. Easily put them in long term green, and can easily continue to develop its pipeline.

$SPRO GSK Peak Sales Target: GSK evaluates Utebzi as part of a trio of new antimicrobial launches. The company suggests these three products will collectively achieve peak sales exceeding £2 billion (~$2.6 billion USD) annually. Now take 35% of that, for a company of 24 people or so, with more in the pipeline.

$SPRO no doubt UK based global GSK wants UK & EU EMA appr of tebi too and under brilliant Tony Wood CSO is already well on their way to get this done asap in '27. GSK will save countless lives, needless hosp visits, make billions of sales globally with it, and imo believe they'll re-negot w spro to own it all, and spro sh value boldly takes off. long and

$SPRO New class of approved antibiotic for UTI with TAM in billion+ Approximately $326 million in remaining potential commercial and sales milestones from GSK under the tebipenem HBr / Utebzi license agreement (as of mid-2026 disclosures), plus tiered royalties. The nearest major one is ~$51 million upon first U.S. commercial sale. $XBI $QQQ $SPY

$SPRO historical statistics, from which quantiative strategies are derived, are bearish but the fundamental Truth here is bullish, Sjogren's is believed to be a $25B that's with a b billion program that its co-developer Innovent is advancing with $SPRO rights to the USA +$120M in net cash will be reported on 9/30/2026 earnings ~$2.10 per share and flip a number of buy programs/screens on to start accumulating $SPRO .....burn going forward will be less than $20M so next year in 9/30/2027 cash will be >$100M $1.76 per share .....and Sjogren's and the IGG4 program....so what's the probability that this doesn't work and they cut the program in 2028? Well hard to say but in 2028 we will still have $83M or $1.43 in cash.....and no major wall street sell-side coverage yet....

$SPRO what happened at the end of the day there with all that volume and the spike up? I didn’t seen any news